{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:31:09Z","timestamp":1788845469031,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although renin-angiotensin system inhibitors (RASi) are the mainstay in the management of heart failure with reduced ejection fraction, chronic kidney disease, and other cardiovascular conditions, they are often discontinued due to hyperkalemia. The prognostic impact of discontinuing RASi after developing hyperkalemia remains uncertain. Using a target trial framework based on the cloning, censoring, and weighting method, we compared discontinuing RASi after incident hyperkalemia with continuing RASi. We identified 2305 patients with an estimated glomerular filtration rate (eGFR) of \u226510\u2009ml\/min\/1.73\u2009m\n                    <jats:sup>2<\/jats:sup>\n                    who developed hyperkalemia (serum potassium levels \u22655.5 mEq\/L) while on RASi in the Osaka Consortium for Kidney Disease Research (OCKR) database. The primary outcome was a composite of initiation of kidney replacement therapy, a \u226550% decline in eGFR, or reaching eGFR &lt;5\u2009ml\/min\/1.73\u2009m\n                    <jats:sup>2<\/jats:sup>\n                    . Secondary outcomes included all-cause death and severe hyperkalemia (serum potassium levels \u22656.5 mEq\/L). The mean (standard deviation) age and eGFR were 68 (14) years and 29 (17) mL\/min\/1.73\u2009m\u00b2, respectively. After developing hyperkalemia, 346 (15%) discontinued RASi. Discontinuing RASi was associated with a 16% [95% confidence interval 2\u201333%] higher hazard of mortality than continuing RASi while the composite kidney outcome did not differ between groups (adjusted hazard ratio [HR] 1.01 [0.81\u20131.26]). Severe hyperkalemia occurred less frequently in those who discontinued RASi than those who continued RASi (adjusted HR 0.83 [0.69, 0.99]). RASi discontinuation after incident hyperkalemia was associated with higher mortality despite a lower risk of severe hyperkalemia. It was not related to kidney outcome. Appropriate clinical decision-making regarding RASi discontinuation may depend on the clinical context.\n                  <\/jats:p>","DOI":"10.1038\/s41440-025-02218-8","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:56:06Z","timestamp":1747191366000},"page":"2034-2044","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Discontinuing renin-angiotensin system inhibitors after incident hyperkalemia and clinical outcomes: target trial emulation"],"prefix":"10.1038","volume":"48","author":[{"given":"Nobuhiro","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koki","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsufumi","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Kusunoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Yamato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mizui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ya","family":"Kaimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"2218_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"S Investigators","year":"1992","unstructured":"Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685\u201391.","journal-title":"N Engl J Med"},{"key":"2218_CR2","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. NEngl J Med. 2003;349:1893\u2013906.","journal-title":"NEngl J Med"},{"key":"2218_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Heart Outcomes Prevention Evaluation Study I, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. NEngl J Med. 2000;342:145\u201353.","journal-title":"NEngl J Med"},{"key":"2218_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. NEngl J Med. 2001;345:851\u201360.","journal-title":"NEngl J Med"},{"key":"2218_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861\u20139.","journal-title":"N Engl J Med"},{"key":"2218_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","volume":"354","author":"FF Hou","year":"2006","unstructured":"Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131\u201340.","journal-title":"N Engl J Med"},{"key":"2218_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"O Investigators","year":"2008","unstructured":"Investigators O, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359.","journal-title":"N Engl J Med"},{"key":"2218_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/j.mayocp.2019.05.031","volume":"94","author":"Y Qiao","year":"2019","unstructured":"Qiao Y, Shin JI, Sang Y, Inker LA, Secora A, Luo S, et al. Discontinuation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Mayo Clin Proc. 2019;94:2220\u20139.","journal-title":"Mayo Clin Proc"},{"key":"2218_CR9","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease.","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes CKDWG. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117\u2013S314.","journal-title":"Kidney Int"},{"key":"2218_CR10","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","volume":"387","author":"S Bhandari","year":"2022","unstructured":"Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med. 2022;387:2021\u201332.","journal-title":"N Engl J Med"},{"key":"2218_CR11","doi-asserted-by":"publisher","unstructured":"Hattori K, Sakaguchi Y, Oka T, Asahina Y, Kawaoka T, Doi Y, et al. Estimated Effect of Restarting Renin-Angiotensin System Inhibitors after Discontinuation on Kidney Outcomes and Mortality. J Am Soc Nephrol. 2024; https:\/\/doi.org\/10.1681\/ASN.0000000000000425.","DOI":"10.1681\/ASN.0000000000000425"},{"key":"2218_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","volume":"80","author":"SJ Leon","year":"2022","unstructured":"Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Sucha E, et al. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study. Am J Kidney Dis. 2022;80:164\u201373.e1.","journal-title":"Am J Kidney Dis"},{"key":"2218_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejim.2024.03.021","volume":"125","author":"S Jimenez-Marrero","year":"2024","unstructured":"Jimenez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Enjuanes C, Yun S, et al. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis. Eur J Intern Med. 2024;125:89\u201397.","journal-title":"Eur J Intern Med"},{"key":"2218_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000531102","volume":"54","author":"J An","year":"2023","unstructured":"An J, Zhou H, Ni L, Harrision TN, Wei R, Agiro A, et al. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes. Am J Nephrol. 2023;54:258\u201367.","journal-title":"Am J Nephrol"},{"key":"2218_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","volume":"24","author":"E Kanda","year":"2023","unstructured":"Kanda E, Rastogi A, Murohara T, Lesen E, Agiro A, Arnold M, et al. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol. 2023;24:18.","journal-title":"BMC Nephrol"},{"key":"2218_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/tri.13081","volume":"31","author":"A Gleiss","year":"2018","unstructured":"Gleiss A, Oberbauer R, Heinze G. An unjustified benefit: immortal time bias in the analysis of time-dependent events. Transpl Int. 2018;31:125\u201330.","journal-title":"Transpl Int"},{"key":"2218_CR17","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","volume":"23","author":"M Trevisan","year":"2021","unstructured":"Trevisan M, Fu EL, Xu Y, Savarese G, Dekker FW, Lund LH, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021;23:1698\u2013707.","journal-title":"Eur J Heart Fail"},{"key":"2218_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ahj.2021.09.014","volume":"243","author":"Y Xu","year":"2022","unstructured":"Xu Y, Fu EL, Trevisan M, Jernberg T, Sjolander A, Clase CM, et al. Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes. Am Heart J. 2022;243:177\u201386.","journal-title":"Am Heart J"},{"key":"2218_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hernan","year":"2016","unstructured":"Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70\u20135.","journal-title":"J Clin Epidemiol"},{"key":"2218_CR20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","volume":"34","author":"EL Fu","year":"2023","unstructured":"Fu EL. Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How? J Am Soc Nephrol. 2023;34:1305\u201314.","journal-title":"J Am Soc Nephrol"},{"key":"2218_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.ajkd.2020.06.019","volume":"77","author":"S Kajimoto","year":"2021","unstructured":"Kajimoto S, Sakaguchi Y, Asahina Y, Kaimori JY, Isaka Y. Modulation of the Association of Hypobicarbonatemia and Incident Kidney Failure With Replacement Therapy by Venous pH: A Cohort Study. Am J Kidney Dis. 2021;77:35\u201343.","journal-title":"Am J Kidney Dis"},{"key":"2218_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/j.ajkd.2021.05.022","volume":"79","author":"Y Asahina","year":"2022","unstructured":"Asahina Y, Sakaguchi Y, Kajimoto S, Hattori K, Doi Y, Oka T, et al. Association of Time-Updated Anion Gap With Risk of Kidney Failure in Advanced CKD: A Cohort Study. Am J Kidney Dis. 2022;79:374\u201382.","journal-title":"Am J Kidney Dis"},{"key":"2218_CR23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/HYPERTENSIONAHA.121.18360","volume":"79","author":"T Oka","year":"2022","unstructured":"Oka T, Sakaguchi Y, Hattori K, Asahina Y, Kajimoto S, Doi Y, et al. Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease. Hypertension. 2022;79:679\u201389.","journal-title":"Hypertension"},{"key":"2218_CR24","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2218_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0248-6","volume":"16","author":"JS Ngwa","year":"2016","unstructured":"Ngwa JS, Cabral HJ, Cheng DM, Pencina MJ, Gagnon DR, LaValley MP, et al. A comparison of time dependent Cox regression, pooled logistic regression and cross sectional pooling with simulations and an application to the Framingham Heart Study. BMC Med Res Methodol. 2016;16:148.","journal-title":"BMC Med Res Methodol"},{"key":"2218_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","volume":"11","author":"MA Hernan","year":"2000","unstructured":"Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561\u201370.","journal-title":"Epidemiology"},{"key":"2218_CR27","first-page":"39","volume":"2","author":"EJ Murray","year":"2020","unstructured":"Murray EJ, Caniglia EC, Petito LC. Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence. Res Methods Med Health Sci. 2020;2:39\u201349.","journal-title":"Res Methods Med Health Sci"},{"key":"2218_CR28","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/sim.7654","volume":"37","author":"M Schomaker","year":"2018","unstructured":"Schomaker M, Heumann C. Bootstrap inference when using multiple imputation. Stat Med. 2018;37:2252\u201366.","journal-title":"Stat Med"},{"key":"2218_CR29","first-page":"E328","volume":"247","author":"DB Young","year":"1984","unstructured":"Young DB, Smith MJ Jr, Jackson TE, Scott RE. Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone. Am Physiological Soc J. 1984;247:E328\u2013E35.","journal-title":"Am Physiological Soc J"},{"key":"2218_CR30","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1172\/JCI119249","volume":"99","author":"S Okubo","year":"1997","unstructured":"Okubo S, Niimura F, Nishimura H, Takemoto F, Fogo A, Matsusaka T, et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Investig. 1997;99:855\u201360.","journal-title":"J Clin Investig"},{"key":"2218_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","volume":"16","author":"A Sato","year":"2003","unstructured":"Sato A. Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003;16:781\u20138.","journal-title":"Am J Hypertens"},{"key":"2218_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.kint.2023.09.012","volume":"105","author":"S Bhandari","year":"2024","unstructured":"Bhandari S, Mehta S, Khawaja A, Cleland JGF, Ives N, Cockwell P. Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease. Kidney Int. 2024;105:200\u20138.","journal-title":"Kidney Int"},{"key":"2218_CR33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1681\/ASN.2020050682","volume":"32","author":"EL Fu","year":"2021","unstructured":"Fu EL, Evans M, Clase CM, Tomlinson LA, van Diepen M, Dekker FW, et al. Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study. J Am Soc Nephrol. 2021;32:424\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"2218_CR34","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","volume":"180","author":"Y Qiao","year":"2020","unstructured":"Qiao Y, Shin JI, Chen TK, Inker LA, Coresh J, Alexander GC, et al. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med. 2020;180:718\u201326.","journal-title":"JAMA Intern Med"},{"key":"2218_CR35","first-page":"10430","volume":"18","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Cherney DZI, Desai AS, Testani JM, Verma S, Chinnakondepalli K, et al. Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure. J Am Coll Cardiol. 2024;18:10430\u20135. S0735-1097.","journal-title":"J Am Coll Cardiol"},{"key":"2218_CR36","doi-asserted-by":"publisher","first-page":"e033755","DOI":"10.1136\/bmjopen-2019-033755","volume":"10","author":"AYY Boo","year":"2020","unstructured":"Boo AYY, Koh YLE, Hu PL, Tan NC. Prevalence and factors associated with false hyperkalaemia in Asians in primary care: a cross-sectional study (the Unlysed Hyperkalaemia- the Unseen Burden (UHUB) study). BMJ Open. 2020;10:e033755.","journal-title":"BMJ Open"},{"key":"2218_CR37","unstructured":"United States Renal Data System. USRDS Annual Data Report: International Comparisons. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. 2024. Available from: https:\/\/usrds-adr.niddk.nih.gov\/2024\/end-stage-renal-disease\/11-international-comparisons (Accessed March 31, 2025)."}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02218-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T18:03:17Z","timestamp":1751824997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-025-02218-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2218"],"URL":"https:\/\/doi.org\/10.1038\/s41440-025-02218-8","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YS and MY disclose receipt of honoraria for lectures from AstraZeneca. RY discloses receipt of honoraria for lectures from Chugai and Novartis. IM discloses receipt of honoraria for lectures from Kyowa Kirin, Kowa, and Sanwa Kagaku Kenkyusyo. IY discloses receipt of consulting fees from Kyowa Kirin and Sanwa Kagaku Kenkyusyo, and honoraria for lectures from AstraZeneca, Kyowa Kirin, Mitsubishi Tanabe, Astellas, and Sanwa Kagaku Kenkyusyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}